Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) announced that Arthur T. Sands, M.D., Ph.D., president and CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 4:30 p.m. PT in San Francisco.

The presentation will be webcast live and accessible via a link in the Investors section of the Nurix website, with the archived webcast available for 30 days after the event.

Key Figures

Conference edition 44th Annual J.P. Morgan Healthcare Conference

Presentation date January 12, 2026 Corporate update at J.P. Morgan Healthcare Conference

Presentation time 4:30 p.m. PT Scheduled conference presentation slot

Webcast availability 30 days Archived webcast access period after the event

Market Reality Check

$18.49 Last Close

Volume Volume 1,469,704 is below the 20-day average of 1,909,566 (relative volume 0.77). normal

Technical Shares trade above the 200-day moving average of 11.94, with price at 18.06.

Peers on Argus

Peers show mixed moves: RIGL -2.4%, RLAY -2.04%, DAWN -4.74% while AVBP +2.72% and PRME +0.86%, suggesting stock-specific factors for NRIX’s -4.8% move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 08	Clinical data update	Positive	+18.7%	Phase 1 bexobrutideg data in Waldenström macroglobulinemia with 75% ORR.
Dec 01	Clinical webcast plan	Neutral	-4.4%	Announcement of webcast to review Phase 1 bexobrutideg data and corporate update.
Nov 25	Conference participation	Neutral	-0.9%	Planned participation in Piper Sandler healthcare conference with fireside chat.
Nov 10	Board appointment	Positive	-0.5%	Appointment of experienced oncology leader Roger Dansey to board of directors.
Nov 07	Clinical data update	Positive	-1.7%	Translational Phase 1 data for NX-1607 showing immune activation and remodeling.

Pattern Detected

Positive clinical data have sometimes led to strong gains but also occasional selloffs, while neutral conference/webcast items have had modest price impact.

Recent Company History

Over the last two months, Nurix highlighted multiple clinical and corporate milestones. On Nov 7, 2025, translational data for NX-1607 were presented, followed by the appointment of Roger Dansey to the board on Nov 10. Participation in the Piper Sandler conference on Nov 25 and an ASH webcast announcement on Dec 1 preceded strong Phase 1 bexobrutideg data at ASH on Dec 8. Today’s J.P. Morgan conference update continues this pattern of regular investor-facing communications.

Market Pulse Summary

This announcement highlights Nurix’s upcoming corporate update at the J.P. Morgan Healthcare Conference on January 12, 2026 at 4:30 p.m. PT, with an archived webcast available for 30 days. It continues a pattern of regular visibility events following recent clinical data disclosures. Investors tracking the story may focus on how management characterizes the development path for its targeted protein degradation programs and any strategic commentary relative to prior clinical updates.

Key Terms

clinical-stage biopharmaceutical medical

"Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company"

A clinical-stage biopharmaceutical is a company that is developing medicines or biological treatments that are currently being tested in people in clinical trials to assess safety and effectiveness. For investors it signals a higher-risk, higher-reward profile: progress through human testing and regulatory milestones can sharply increase value if results are positive, while failed trials can wipe out expected future revenue — like a prototype that must prove it works before it can be sold widely.

targeted protein degradation medical

"focused on the discovery, development and commercialization of targeted protein degradation medicines"

Targeted protein degradation is a drug approach that uses small molecules to mark harmful or malfunctioning proteins inside cells so the cell’s own disposal system breaks them down, rather than simply blocking their activity. For investors, it matters because this method can potentially tackle diseases that traditional drugs cannot reach, offering a new class of therapies with broad commercial and patent potential—like switching from silencing a problem to removing it entirely.

autoimmune diseases medical

"targeted protein degradation medicines in oncology and autoimmune diseases"

Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own cells, tissues or organs, causing chronic inflammation and damage—think of the immune system as a home security system that wrongly targets the house instead of intruders. Investors care because these illnesses create sustained demand for diagnostics, long-term treatments and specialty drugs, influence regulatory scrutiny and healthcare costs, and can shape the commercial outlook for biotech and pharmaceutical investments.

AI-generated analysis. Not financial advice.

BRISBANE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30 p.m. PT in San Francisco.

The presentation will be webcast live and can be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event.

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6 in collaboration with Sanofi, a clinical stage degrader of IRAK4 in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information visit http://www.nurixtx.com.

Contacts:

Investors
Kris Fortner
Nurix Therapeutics, Inc.
kfortner@nurixtx.com

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

Kris Fortner
Nurix Therapeutics, Inc.
Kfortner@nurixtx.com

FAQ

When will Nurix (NRIX) present at the 44th Annual J.P. Morgan Healthcare Conference?

Nurix will present on Monday, January 12, 2026 at 4:30 p.m. PT.

Who will deliver Nurix's (NRIX) corporate update at the J.P. Morgan conference?

Arthur T. Sands, M.D., Ph.D., president and chief executive officer, will deliver the update.

How can investors watch Nurix's (NRIX) presentation at the J.P. Morgan conference?

The presentation will be webcast live and accessible via a link in the Investors section of the Nurix website.

Will Nurix's (NRIX) J.P. Morgan presentation be available after the live event?

Yes, an archived webcast will be available for 30 days after the event.

What topics will Nurix (NRIX) cover in the January 12, 2026 corporate update?

The company announced a corporate update presentation; specific agenda details were not provided in the announcement.

Where is the 44th Annual J.P. Morgan Healthcare Conference presentation by Nurix (NRIX) being held?

The presentation is scheduled for San Francisco as part of the conference on January 12, 2026.